The global Parkinson’s disease treatment market size was estimated at around USD 4.3 billion in 2021 and it is projected to hit around USD 12.1 billion by 2030, growing at a CAGR of 12.18% from 2022 to 2030.
The global Parkinson’s disease treatment market size was estimated at around USD 4.3 billion in 2021 and it is projected to hit around USD 12.1 billion by 2030, growing at a CAGR of 12.18% from 2022 to 2030.
Report Highlights
- The Carbidopa-levodopa drug class segment dominated the industry with a revenue share of more than 25.02% in 2021.
- The retail pharmacy segment dominated the global industry in 2021 and accounted for the largest share of 59.2% of the overall revenue.
- North America dominated the global industry with a maximum revenue share of 37.95% in 2021.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39856
In August 2021, the Parkinson’s Foundation announced an investment of USD 43 million as a research grant to 29 research projects having the goal of developing novel treatments and therapies for PD. In addition, in May 2021, the Parkinson’s Foundation announced an investment of USD 10 million for research, care, and educational programs related to Parkinson’s Disease (PD). This investment may aid in providing awareness and genetic testing free of cost to people suffering from PD.
Such investment initiatives are expected to boost industry growth. In the last ten years, there have been significant R&D activities in the PD therapy sector, leading to the development of innovative drug-delivery methods. Due to fewer side effects, these cutting-edge drug delivery systems outperform the existing ones. In addition, the rate of prescription for these techniques has increased due to a rise in patient compliance, which is fueling the expansion of the industry. Moreover, key pharmaceutical companies are undertaking initiatives, such as collaborations and partnerships, for the development, manufacturing & commercialization of products to meet the rising demand for disease treatment in the international market.
For instance, in November 2021, STADA Arzneimittel and Bioglan formed a partnership to expand the production capacity of the medicine Lecigon (levodopa/carbidopa/entacapone) used to treat patients with PD. Thus, increasing demand for medicines that are used to treat patients with PD is anticipated to drive industry growth. However, the limited availability of neurologists leads to issues, such as longer waiting times for patients and difficulty in hiring new neurosurgeons in hospitals. In addition, some of the currently practicing neurologists avoid accepting new Medicaid patients, which creates difficulty for patients who want to switch to another doctor. According to the American Academy of Neurology (AAN) report, around 19% shortage of neurologists is projected by 2025.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 4.3 billion |
| Revenue Forecast by 2030 | USD 12.1 billion |
| Growth rate from 2022 to 2030 | CAGR of 12.18% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Drug class, distribution channel, region |
| Companies Covered | Cerevel Therapeutics; Novartis AG; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; GlaxoSmithKline plc. (GSK); AbbVie, Inc.; H. Lundbeck A/S; Amneal Pharmaceuticals LLC; Supernus Pharmaceuticals, Inc. |
Industry Dynamics
Growth Drivers
The market is anticipated to rise due to the strong pipeline of new medications for the condition. For instance, in October 2021, Appello Pharmaceuticals Inc., a diagnostic and therapeutic company dedicated to finding novel early-stage drug targets for patients with neurological disorders, started phase 1 clinical studies of a Parkinson’s disease potential drug formed at the Warren Center for Neuroscience Drug Discovery. The mGlu4 PAM AP-472 is designed to work with levodopa, a currently available treatment for Parkinson’s disease, to extend the time that patients experience relief from their Parkinson’s illnesses without suffering from crippling side effects like dyskinesias—uncontrollable unconscious movements.
Additionally, in May 2021, PharmaTher Holdings Ltd. is excited to announce that the U.S. Food and Drug Administration has confirmed the Firm’s Investigational New Drug (“IND”) application to move forward with a Phase 2 clinical trial to assess the safety, effectiveness, and pharmacokinetic properties of ketamine in the diagnosis of dopamine antagonists dyskinesia in patients suffering from Parkinson’s disease. Thus, the major drugs in clinical development are the factor that is boosting the market growth over the forecast period.
Furtherly, the increasing number of generic drug manufacturers along with rising research and development spending from government and private firms are also lifting the market growth in the above-mentioned forecast period
Restraint
Rising side effects associated with drugs used in Parkinson’s disease therapeutic is projected to hamper the market growth during the forecast period. The Parkinson’s disease drugs side effects will have a negative impact on patient’s lives and have to be kept under control along with the symptoms. Impulsive and compulsive behavior are possible side effects of some Parkinson’s disease medications and can have a significant impact on the affected person. In addition the available medications may have an effect of blocking the Parkinson’s medications or interact in a way making symptoms worse.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39856
Drug Class Insights
The Carbidopa-levodopa drug class segment dominated the industry with a revenue share of more than 25.02% in 2021. This growth was attributed to the high prescription rate of these drugs. According to the U.S. Drug Use Statistics, the estimated number of Carbidopa-Levodopa prescriptions was found to be 527,530 for 183,690 Parkinson’s patients in 2020. Carbidopa and Levodopa are a combination of medicines indicated to treat symptoms of PD. It is the most potent and highly used medication for PD as a second line of treatment. It is primarily available in the oral route of administration, such as in the form of immediate-release tablets, controlled-release tablets, enteral suspension, and extended-release capsules.
Furthermore, the presence of pipeline candidates such as LY03003, coupled with a rise in the demand for dopamine agonists, are factors expected to positively contribute to segment growth. According to the American PD Association (APDA), currently, there are four FDA-approved Dopamine Agonists, which include Requip (ropinirole), Mirapex (pramipexole), Apokyn (apomorphine), and Neupro (rotigotine), available in the U.S. to treat patients suffering from PD. Ropinirole and Pramipexol are available in both long-acting and regular formulations. Apomorphine is delivered by intravenous injection and is considered rescue medication within 10 minutes. Therefore, the approval of novel medicines for the treatment of the disease will also drive segment growth.
Distribution Channel Insights
The retail pharmacy segment dominated the global industry in 2021 and accounted for the largest share of 59.2% of the overall revenue. The segment is anticipated to expand further at the fastest growth rate during the forecast period. According to Parkinson’s news today, PD affects around 41 individuals per 100,000 in their 40s, to more than 1,900 people per 100,000 in their 80s and 90s. It is the second-most common neurodegenerative disorder after Alzheimer’s disease. Currently, PD is not completely curable and it takes lifelong support of medications. The majority of this medication consumption is associated with retail pharmacies. All these factors are expected to propel the segment growth during the projection period.
Furthermore, the ease of availability of PD drugs including generic carbidopa-levodopa, pramipexole dihydrochloride, selegiline hydrochloride, and others in retail pharmacy chains, such as Walgreens and Walmart Stores, boosts the segment growth. The online pharmacy segment is expected to witness a significant growth rate during the forecast period. The trend of online shopping is growing due to the comfort, flexibility, and convenience offered by these platforms. This, in turn, is generating high revenues, thereby driving the growth of the online segment. Moreover, online shopping offers various discounts, benefiting customers. This factor is expected to boost the demand for online pharmacies during the forecast period.
Regional Insights
North America dominated the global industry with a maximum revenue share of 37.95% in 2021. This dominance can be attributed to the presence of leading players in the region, such as AbbVie Inc., Merck & Co. Inc., Amneal Pharmaceuticals LLC., and Sunovion Pharmaceuticals Inc. These players support growth by introducing new PD symptom management products. For instance, in May 2020, the U.S. FDA approved Kynmobi developed by Sunovion Pharmaceuticals Inc., to treat off-episodes in patients with PD. Furthermore, extensive research in the field of PD in the region is anticipated to positively contribute to the market growth.
For instance, in Canada, in January 2022, BlueRock Therapeutics administered the first dose of DA01 (dopaminergic neurons) in patients with advanced PD. Successful completion of the trial and subsequent approval of the product is anticipated to drive the region’s growth during the forecast period. Asia Pacific is estimated to register the fastest growth rate during the assessment period. This is due to the increased product penetration, untapped potential, and growing prevalence of PD in developing countries. For instance, in July 2022, UCB S.A. received an Import Drug License (IDL) from the China Food and Drug Administration (CFDA) for the supply and delivery of Neupro in China. Neupro is recommended as a monotherapy in combination with levodopa to treat patients with early-stage idiopathic PD.
Key Players
- Cerevel Therapeutics
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- GlaxoSmithKline plc. (GSK)
- AbbVie, Inc.
- H. Lundbeck A/S
- Amneal Pharmaceuticals LLC
- Supernus Pharmaceuticals, Inc.
Market Segmentation
- By Drug Class Outlook
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- By Distribution Channel Outlook
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Regional Outlook
- North America
-
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39856
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/